New River Pharmaceuticals Inc. could receive $500 million in a collaboration deal with Shire Pharmaceuticals Group plc for global commercialization of New River's Phase III compound being developed for attention deficit hyperactivity disorder. (BioWorld Today)

Despite experiencing a 24 percent increase in product sales and a 26 percent increase in adjusted earning, Amgen Inc. missed its earning expectations for the fourth quarter. (BioWorld Today)

Despite experiencing a 24 percent increase in product sales and a 26 percent increase in adjusted earning, Amgen Inc. missed its earning expectations for the fourth quarter. (BioWorld Today)